AHA GUIDELINES Bundle (free trial)

Heart Failure Stage 3 Pharmacological Therapy

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/700053

Contents of this Issue

Navigation

Page 1 of 5

Table 1. Pharmacological Treatment for Stage C HF With Reduced Ejection Fraction: Recommendations COR LOE Recommendations I e clinical strategy of inhibition of the renin-angiotensin system with: A ACE inhibitors, OR A ARBs, OR B-R ARNI* in conjunction with evidence-based beta blockers, and aldosterone antagonists in selected patients, is recommended for patients with chronic HFrEF to reduce morbidity and mortality. I A e use of ACE inhibitors is beneficial for patients with prior or current symptoms of chronic HFrEF to reduce morbidity and mortality. I A e use of ARBs to reduce morbidity and mortality is recommended in patients with prior or current symptoms of chronic HFrEF who are intolerant to ACE inhibitors because of cough or angioedema. I B-R In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality. III: Harm B-R ARNI should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor. III: Harm C-EO ARNI should not be administered to patients with a history of angioedema. Table 2. Ivabradine: Recommendation COR LOE Recommendation IIa B-R Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II-III) stable chronic HFrEF (LVEF ≤35%) who are receiving GDEM, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest. Recommendations * sacubitril/valsartan is the only FDA approved ARNI.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Heart Failure Stage 3 Pharmacological Therapy